G. Orvoën

ORCID: 0000-0002-0982-4204
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Dementia and Cognitive Impairment Research
  • Frailty in Older Adults
  • Nutrition and Health in Aging
  • SARS-CoV-2 and COVID-19 Research
  • Colorectal Cancer Treatments and Studies
  • Respiratory viral infections research
  • Diet and metabolism studies
  • Cancer Treatment and Pharmacology
  • Heart Failure Treatment and Management
  • Health, Medicine and Society
  • Technology Use by Older Adults
  • Cancer survivorship and care
  • Aging, Elder Care, and Social Issues
  • Healthcare Systems and Practices
  • SARS-CoV-2 detection and testing
  • Economic and Financial Impacts of Cancer
  • Atrial Fibrillation Management and Outcomes
  • Tracheal and airway disorders
  • Cholesterol and Lipid Metabolism
  • Cancer, Hypoxia, and Metabolism
  • Cardiac, Anesthesia and Surgical Outcomes
  • Lipoproteins and Cardiovascular Health
  • Angiogenesis and VEGF in Cancer
  • Congenital Heart Disease Studies
  • COVID-19 Clinical Research Studies

Hôpital Broca
2009-2022

Assistance Publique – Hôpitaux de Paris
2013-2022

Hôpital de Vaugirard-Gabriel Pallez
2021

Université Paris Cité
2010-2020

Paris Cardiovascular Research Center
2016

Hôpital Cochin
2016

Délégation Paris 5
2010-2016

Descartes (Belgium)
2016

Sorbonne Paris Cité
2014

Direct oral anticoagulants have been evaluated in the general population, but proper evidence for their safe use geriatric population is still missing. We compared bleeding risk of a direct anticoagulant (rivaroxaban) and vitamin K antagonists (VKAs) among French patients with non-valvular atrial fibrillation (AF) aged ≥80 years.We performed sequential observational prospective cohort study, using data from 33 centres. The sample comprised 908 newly initiated on VKAs between September 2011...

10.1136/heartjnl-2020-317923 article EN Heart 2020-12-01

In older patients with cancer, depression is difficult to assess because of its heterogeneous clinical expression. The 4-item version the Geriatric Depression Scale (GDS-4) quick and easy administer but has not been validated in this population. present study was designed test diagnostic performance GDS-4 a French cohort cancer before treatment.Our cross-sectional analysis data from Elderly Cancer Patient covered all aged ≥70 years referred for geriatric assessment at two centers France...

10.1002/onco.13746 article EN The Oncologist 2021-03-08

170 Background: Older age is a cause of disparity in cancer treatment decision and guidelines for patients with comorbidities, polypharmacy, denutrition or psycho-social frailty are needed. A pre-therapeutic multidimensional assessment might improve the complex patient management. We developed an experimental program integrated medicine called ARIANE. report 18 months activity this outpatient setting evaluation, its feasibility impact on decision-making. Methods: Complex predefined strategy...

10.1200/jco.2014.32.31_suppl.170 article EN Journal of Clinical Oncology 2014-11-01

Abstract The mechanisms that allowed for the SARS-CoV-2 B.1.1.7 variant to rapidly outcompete pre-existing variants in many countries remain poorly characterized. Here, we analyzed viral release, anti-SARS-CoV-2 antibodies and cytokine production a retrospective series of 427 RT–qPCR+ nasopharyngeal swabs collected COVID-19 patients harbouring either non-B.1.1.7 or B.1.17 variants. We utilized novel rapid assay, based on S-Fuse-T reporter cells, quantify infectious SARS-CoV-2. With both...

10.1101/2021.05.20.21257393 preprint EN cc-by-nc-nd medRxiv (Cold Spring Harbor Laboratory) 2021-05-22

Older age and associated comorbid conditions increase the risk of severe form COVID-19 death. The SARS-CoV-2 vaccination campaign began in France December 2020 targeting institutionalized older population before having been evaluated this population. objective our study was to assess tolerability 21 days (D21) 90 after first (D90) old people. Secondary its effectiveness (mortality, hospitalization occurrence COVID) at D21 D90. People living nursing homes or long-term facilities were included...

10.1186/s12877-024-05609-7 article EN cc-by-nc-nd BMC Geriatrics 2024-12-23

9551 Background: Older age is a cause of disparity in cancer treatment decision. Treatment guidelines for patients with comorbidities, polypharmacy, denutrition or psycho-social frailty are needed. A pre-therapeutic multidimensional assessment might improve the unfit patient management. We developed an experimental program integrated medicine called ARIANE. report 18 months activity this outpatient setting evaluation, its feasibility and impact on decision-making. Methods: Unfit predefined...

10.1200/jco.2014.32.15_suppl.9551 article EN Journal of Clinical Oncology 2014-05-20

e20523 Background: Elderly people represent a growing population susceptible to be treated with sunitinib (SU). The aim of this retrospective study was explore the relationship between SU exposure and occurrence dose-limiting toxicities (DLT) in real-life elderly patients. Methods: patients(>70 years old) received at starting dose 50 mg per day (4 weeks on/2 off) (standard regimen, SR) or continuous daily 25 37.5 (adapted AR) after multidisciplinary risk assessment. DLT during first cycle (6...

10.1200/jco.2014.32.15_suppl.e20523 article EN Journal of Clinical Oncology 2014-05-20

Purpose: To evaluate the interest of BNP for heart failure (HF) diagnosis in very old patients. Methods: The BED Study is a French multicenter observational prospective study that enrolled 383 patients (≥ 80 y) hospitalized geriatric care with acute dyspnea. was measured phase, before any diuretic treatment. Cardiologists, blinded values, classified into 3 subgroups according to ESC criteria: HF, respiratory and mixed disease (HF respiratory). discriminating value HF assessed by sensibility,...

10.1093/eurheartj/eht309.p4211 article EN European Heart Journal 2013-08-02
Coming Soon ...